المؤلفون: Ryan V. Quiroz (10359236), Michael H. Reutershan (2470597), Sebastian E. Schneider (2198083), David Sloman (10359430), Brian M. Lacey (2135143), Brooke M. Swalm (10359433), Charles S. Yeung (2302963), Craig Gibeau (1586212), Daniel S. Spellman (2649097), Danica A. Rankic (1858132), Dapeng Chen (528941), David Witter (10359239), Doug Linn (10359436), Erik Munsell (10359439), Guo Feng (413683), Haiyan Xu (148626), Jonathan M. E. Hughes (6912470), Jongwon Lim (163671), Josep Saurí (1523239), Kristin Geddes (10359442), Murray Wan (10359445), My Sam Mansueto (3384113), Nicole E. Follmer (10359448), Patrick S. Fier (1333728), Phieng Siliphaivanh (1822588), Pierre Daublain (1625986), Rachel L. Palte (8299626), Robert P. Hayes (9220508), Sandra Lee (273007), Shuhei Kawamura (1407448), Steven Silverman (10359451), Sulagna Sanyal (2918147), Timothy J. Henderson (2397364), Yingchun Ye (2032282), Yuanwei Gao (3951080), Benjamin Nicholson (2035678), Michelle R. Machacek (2639716)

مصطلحات موضوعية: Biochemistry, Medicine, Genetics, Molecular Biology, Pharmacology, Hematology, Infectious Diseases, Biological Sciences not elsewhere classified, Chemical Sciences not elsewhere classified, novel designs, Novel Classes, balancing bioavailability, structure-based drug designs, DNA repair, type II arginine methyltransferase, Additional efforts, optimization strategies, bicyclic nucleoside-derived classes, protein substrates, identification, dose projections, PRMT 5 activity, Cancer Protein arginine methyltrans., RNA, CYP 3A inhibition, strain energy calculations, compound docking, vivo activity, PRMT 5, PRMT 5 inhibitors

Relation: https://figshare.com/articles/journal_contribution/The_Discovery_of_Two_Novel_Classes_of_5_5-Bicyclic_Nucleoside-Derived_PRMT5_Inhibitors_for_the_Treatment_of_Cancer/14272906

الاتاحة: https://doi.org/10.1021/acs.jmedchem.0c02083.s001

المؤلفون: Ryan V. Quiroz (10359236), Michael H. Reutershan (2470597), Sebastian E. Schneider (2198083), David Sloman (10359430), Brian M. Lacey (2135143), Brooke M. Swalm (10359433), Charles S. Yeung (2302963), Craig Gibeau (1586212), Daniel S. Spellman (2649097), Danica A. Rankic (1858132), Dapeng Chen (528941), David Witter (10359239), Doug Linn (10359436), Erik Munsell (10359439), Guo Feng (413683), Haiyan Xu (148626), Jonathan M. E. Hughes (6912470), Jongwon Lim (163671), Josep Saurí (1523239), Kristin Geddes (10359442), Murray Wan (10359445), My Sam Mansueto (3384113), Nicole E. Follmer (10359448), Patrick S. Fier (1333728), Phieng Siliphaivanh (1822588), Pierre Daublain (1625986), Rachel L. Palte (8299626), Robert P. Hayes (9220508), Sandra Lee (273007), Shuhei Kawamura (1407448), Steven Silverman (10359451), Sulagna Sanyal (2918147), Timothy J. Henderson (2397364), Yingchun Ye (2032282), Yuanwei Gao (3951080), Benjamin Nicholson (2035678), Michelle R. Machacek (2639716)

مصطلحات موضوعية: Biochemistry, Medicine, Genetics, Molecular Biology, Pharmacology, Hematology, Infectious Diseases, Biological Sciences not elsewhere classified, Chemical Sciences not elsewhere classified, novel designs, Novel Classes, balancing bioavailability, structure-based drug designs, DNA repair, type II arginine methyltransferase, Additional efforts, optimization strategies, bicyclic nucleoside-derived classes, protein substrates, identification, dose projections, PRMT 5 activity, Cancer Protein arginine methyltrans., RNA, CYP 3A inhibition, strain energy calculations, compound docking, vivo activity, PRMT 5, PRMT 5 inhibitors

Relation: https://figshare.com/articles/dataset/The_Discovery_of_Two_Novel_Classes_of_5_5-Bicyclic_Nucleoside-Derived_PRMT5_Inhibitors_for_the_Treatment_of_Cancer/14272912

الاتاحة: https://doi.org/10.1021/acs.jmedchem.0c02083.s003

المؤلفون: Ryan V. Quiroz (10359236), Michael H. Reutershan (2470597), Sebastian E. Schneider (2198083), David Sloman (10359430), Brian M. Lacey (2135143), Brooke M. Swalm (10359433), Charles S. Yeung (2302963), Craig Gibeau (1586212), Daniel S. Spellman (2649097), Danica A. Rankic (1858132), Dapeng Chen (528941), David Witter (10359239), Doug Linn (10359436), Erik Munsell (10359439), Guo Feng (413683), Haiyan Xu (148626), Jonathan M. E. Hughes (6912470), Jongwon Lim (163671), Josep Saurí (1523239), Kristin Geddes (10359442), Murray Wan (10359445), My Sam Mansueto (3384113), Nicole E. Follmer (10359448), Patrick S. Fier (1333728), Phieng Siliphaivanh (1822588), Pierre Daublain (1625986), Rachel L. Palte (8299626), Robert P. Hayes (9220508), Sandra Lee (273007), Shuhei Kawamura (1407448), Steven Silverman (10359451), Sulagna Sanyal (2918147), Timothy J. Henderson (2397364), Yingchun Ye (2032282), Yuanwei Gao (3951080), Benjamin Nicholson (2035678), Michelle R. Machacek (2639716)

مصطلحات موضوعية: Biochemistry, Medicine, Genetics, Molecular Biology, Pharmacology, Hematology, Infectious Diseases, Biological Sciences not elsewhere classified, Chemical Sciences not elsewhere classified, novel designs, Novel Classes, balancing bioavailability, structure-based drug designs, DNA repair, type II arginine methyltransferase, Additional efforts, optimization strategies, bicyclic nucleoside-derived classes, protein substrates, identification, dose projections, PRMT 5 activity, Cancer Protein arginine methyltrans., RNA, CYP 3A inhibition, strain energy calculations, compound docking, vivo activity, PRMT 5, PRMT 5 inhibitors

Relation: https://figshare.com/articles/dataset/The_Discovery_of_Two_Novel_Classes_of_5_5-Bicyclic_Nucleoside-Derived_PRMT5_Inhibitors_for_the_Treatment_of_Cancer/14272909

الاتاحة: https://doi.org/10.1021/acs.jmedchem.0c02083.s002